RxDoctor Payments DataLook up a doctor →

Micheal Macken, MD

Clinical Neurophysiology · Chicago, ILNPI 1336110550

Payments from drug & device makers

$864,482in general payments, 2019–2025

Across 786 payments — averaging $1099.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$490K
  • UCB, Inc.$188K
  • SK Life Science, Inc.$100K
  • Jazz Pharmaceuticals Inc.$51K
  • Sunovion Pharmaceuticals Inc.$14K
  • Greenwich Biosciences, Inc.$10K
  • plus $13K from 4 others

What the payments were for

  • Consulting fees$40,5997%
  • Speaking & faculty fees$431,39378%
  • Travel & lodging$63,68511%
  • Food & beverage$19,3393%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$114,972
Medicare patients
503
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam166$425,593
XcopriCenobamate115$184,585
FycompaPerampanel78$151,499
FinteplaFenfluramine Hcl11$106,752
NayzilamMidazolam51$61,325
KeppraLevetiracetam28$49,856
Lacosamide225$45,224
Felbamate32$28,024
Clobazam212$25,341
LamictalLamotrigine15$24,305
Lamotrigine ErLamotrigine41$18,458
Levetiracetam292$17,492
Divalproex Sodium80$7,099
Levetiracetam ErLevetiracetam66$5,196
Carbamazepine ErCarbamazepine38$5,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Fintepla, Nayzilam$187,671$593,670228 claims
SK Life Science, Inc.Xcopri$99,772$184,585115 claims
UCB SAKeppra$2,938$49,85628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Illinoison file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →